Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I randomized, double-blind, placebo-controlled second investigational triple combination therapy trial of of GLPG3067, GLPG2222 and GLPG2737 in healthy volunteers

Trial Profile

A phase I randomized, double-blind, placebo-controlled second investigational triple combination therapy trial of of GLPG3067, GLPG2222 and GLPG2737 in healthy volunteers

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galicaftor (Primary) ; GLPG 2737 (Primary) ; GLPG 3067 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 28 Jun 2018 According to a Galapagos NV media release, AbbVie has decided not to proceed with this study.
    • 28 Jun 2018 Status changed from recruiting to discontinued, according to a Galapagos NV media release.
    • 05 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top